CL2013003372A1 - Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. - Google Patents
Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.Info
- Publication number
- CL2013003372A1 CL2013003372A1 CL2013003372A CL2013003372A CL2013003372A1 CL 2013003372 A1 CL2013003372 A1 CL 2013003372A1 CL 2013003372 A CL2013003372 A CL 2013003372A CL 2013003372 A CL2013003372 A CL 2013003372A CL 2013003372 A1 CL2013003372 A1 CL 2013003372A1
- Authority
- CL
- Chile
- Prior art keywords
- spiro
- oxacins
- oxacepins
- bace2
- bace1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11167835 | 2011-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003372A1 true CL2013003372A1 (es) | 2014-07-25 |
Family
ID=46177417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003372A CL2013003372A1 (es) | 2011-05-27 | 2013-11-25 | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9079919B2 (es) |
| EP (1) | EP2714697B1 (es) |
| JP (1) | JP2014515382A (es) |
| KR (1) | KR20140048137A (es) |
| CN (1) | CN103596961B (es) |
| AU (1) | AU2012264875B2 (es) |
| BR (1) | BR112013030281A2 (es) |
| CA (1) | CA2833813A1 (es) |
| CL (1) | CL2013003372A1 (es) |
| CO (1) | CO6801773A2 (es) |
| CR (1) | CR20130580A (es) |
| EA (1) | EA024286B1 (es) |
| EC (1) | ECSP13013048A (es) |
| ES (1) | ES2600636T3 (es) |
| IL (1) | IL229334A (es) |
| MA (1) | MA35191B1 (es) |
| MX (1) | MX2013013910A (es) |
| PE (1) | PE20141205A1 (es) |
| SG (1) | SG194835A1 (es) |
| UA (1) | UA111847C2 (es) |
| WO (1) | WO2012163790A1 (es) |
| ZA (1) | ZA201308395B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007049532A1 (ja) | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | アミノジヒドロチアジン誘導体 |
| WO2008133274A1 (ja) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | 環式基で置換されたアミノジヒドロチアジン誘導体 |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| WO2009151098A1 (ja) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
| WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| US9181236B2 (en) | 2011-08-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
| EA026380B1 (ru) | 2012-05-30 | 2017-04-28 | Коментис, Инк. | Соединения хроманов |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| EP2934534B1 (en) | 2012-12-21 | 2017-12-13 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| AU2014225604B2 (en) | 2013-03-08 | 2018-05-17 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| WO2015038446A1 (en) | 2013-09-13 | 2015-03-19 | Merck Sharp & Dohme Corp. | C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use |
| MX2017001794A (es) | 2014-08-08 | 2017-06-29 | Amgen Inc | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
| AR102202A1 (es) | 2014-10-07 | 2017-02-08 | Astrazeneca Ab | Compuestos de oxazol y su uso como inhibidores de bace de oxazol |
| PE20171349A1 (es) | 2015-03-20 | 2017-09-13 | Hoffmann La Roche | Inhibidores de bace1 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1501805A1 (en) | 2002-05-09 | 2005-02-02 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
| SV2006002232A (es) * | 2004-09-21 | 2006-05-25 | Lilly Co Eli | Inhibidores bace ref. x-16940 |
| US8211904B2 (en) * | 2005-07-18 | 2012-07-03 | Merck, Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2007049532A1 (ja) * | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | アミノジヒドロチアジン誘導体 |
| US20100298342A1 (en) | 2006-09-07 | 2010-11-25 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| AU2009277485B2 (en) * | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| US8450308B2 (en) | 2008-08-19 | 2013-05-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| JPWO2010047372A1 (ja) * | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| WO2010073078A2 (en) | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
| US8461160B2 (en) * | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| UY32799A (es) * | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| US8188079B2 (en) * | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| WO2011058763A1 (ja) * | 2009-11-13 | 2011-05-19 | 塩野義製薬株式会社 | アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体 |
| US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| WO2011123674A1 (en) * | 2010-03-31 | 2011-10-06 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| JP2012250933A (ja) * | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
-
2012
- 2012-05-21 US US13/476,094 patent/US9079919B2/en not_active Expired - Fee Related
- 2012-05-24 ES ES12724116.4T patent/ES2600636T3/es active Active
- 2012-05-24 JP JP2014513129A patent/JP2014515382A/ja active Pending
- 2012-05-24 CN CN201280025801.2A patent/CN103596961B/zh not_active Expired - Fee Related
- 2012-05-24 MX MX2013013910A patent/MX2013013910A/es unknown
- 2012-05-24 EA EA201391752A patent/EA024286B1/ru not_active IP Right Cessation
- 2012-05-24 AU AU2012264875A patent/AU2012264875B2/en not_active Expired - Fee Related
- 2012-05-24 CA CA2833813A patent/CA2833813A1/en not_active Abandoned
- 2012-05-24 SG SG2013082607A patent/SG194835A1/en unknown
- 2012-05-24 WO PCT/EP2012/059688 patent/WO2012163790A1/en active Application Filing
- 2012-05-24 KR KR1020137033959A patent/KR20140048137A/ko not_active Application Discontinuation
- 2012-05-24 PE PE2013002577A patent/PE20141205A1/es not_active Application Discontinuation
- 2012-05-24 UA UAA201315118A patent/UA111847C2/uk unknown
- 2012-05-24 EP EP12724116.4A patent/EP2714697B1/en not_active Not-in-force
- 2012-05-24 BR BR112013030281A patent/BR112013030281A2/pt not_active IP Right Cessation
-
2013
- 2013-11-07 ZA ZA2013/08395A patent/ZA201308395B/en unknown
- 2013-11-07 CR CR20130580A patent/CR20130580A/es unknown
- 2013-11-07 IL IL229334A patent/IL229334A/en not_active IP Right Cessation
- 2013-11-13 CO CO13267226A patent/CO6801773A2/es not_active Application Discontinuation
- 2013-11-25 EC ECSP13013048 patent/ECSP13013048A/es unknown
- 2013-11-25 CL CL2013003372A patent/CL2013003372A1/es unknown
- 2013-12-18 MA MA36582A patent/MA35191B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391752A1 (ru) | 2014-04-30 |
| EP2714697A1 (en) | 2014-04-09 |
| EA024286B1 (ru) | 2016-09-30 |
| JP2014515382A (ja) | 2014-06-30 |
| SG194835A1 (en) | 2013-12-30 |
| MA35191B1 (fr) | 2014-06-02 |
| ZA201308395B (en) | 2014-07-30 |
| BR112013030281A2 (pt) | 2016-11-29 |
| CN103596961B (zh) | 2016-09-28 |
| ES2600636T3 (es) | 2017-02-10 |
| AU2012264875B2 (en) | 2017-04-27 |
| NZ616817A (en) | 2015-12-24 |
| AU2012264875A1 (en) | 2013-10-31 |
| ECSP13013048A (es) | 2014-01-31 |
| MX2013013910A (es) | 2014-01-24 |
| IL229334A (en) | 2017-02-28 |
| UA111847C2 (uk) | 2016-06-24 |
| CA2833813A1 (en) | 2012-12-06 |
| PE20141205A1 (es) | 2014-09-22 |
| CO6801773A2 (es) | 2013-11-29 |
| KR20140048137A (ko) | 2014-04-23 |
| WO2012163790A1 (en) | 2012-12-06 |
| US20120302549A1 (en) | 2012-11-29 |
| CR20130580A (es) | 2013-12-09 |
| CN103596961A (zh) | 2014-02-19 |
| IL229334A0 (en) | 2014-01-30 |
| US9079919B2 (en) | 2015-07-14 |
| EP2714697B1 (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| CL2013003025A1 (es) | Compuestos derivados de pirimidinas de diaminocarboxamida y diaminocarbonitrilo, como inhibidores de quinasa jnk; composicion farmaceutica; metodo de inhibicion in vitro; y su uso en el tratamiento o prevencion de trastornos fibroticos del higado, diabetes o sindrome metabolico conduciendo a trastornos fibroticos del higado. | |
| CL2013001295A1 (es) | Compuestos derivados de 2,3-dihidromidazo (1,2-c) quinazolina sustituidos con aminoalcoholes; compuesto intermediario y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis. | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
| CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
| BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
| CL2011001299A1 (es) | Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer. | |
| CL2015002606A1 (es) | Compuesto. | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer |